Karyopharm Therapeutics Inc. Cash and Restricted Cash
Karyopharm Therapeutics Inc. (KPTI) had Cash and Restricted Cash of $55.30 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $55.30M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $91.17M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60.89M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38.02M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $55.30M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $91.17M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $60.89M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $38.02M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $39.08M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $39.12M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $62.81M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $73.17M 10-Q · filed 2025-11-03 |
| 2024-06-30 | $85.11M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $31.39M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $53.19M 10-K · filed 2026-02-13 |
| 2023-09-30 | $44.58M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $81.85M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $85.54M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $136.88M 10-K · filed 2026-02-13 |
| 2022-09-30 | $73.06M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $84.03M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $154.91M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $197.44M 10-K · filed 2025-02-19 |
| 2021-09-30 | $140.44M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $142.71M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $90.00M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $89.12M 10-K · filed 2024-02-29 |
| 2020-09-30 | $84.11M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $105.73M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $203.95M 10-Q · filed 2021-05-04 |
| 2019-12-31 | $130.69M 10-K · filed 2023-02-17 |
| 2019-09-30 | $168.72M 10-Q · filed 2020-11-02 |
| 2019-06-30 | $76.26M 10-Q · filed 2020-08-04 |
| 2019-03-31 | $84.22M 10-Q · filed 2020-05-05 |
| 2018-12-31 | $118.74M 10-K · filed 2022-03-01 |
| 2018-09-30 | $102.31M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $119.60M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $37.79M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $69.49M 10-K · filed 2021-02-24 |
| 2017-09-30 | $54.94M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $55.87M 10-Q · filed 2018-08-07 |
| 2017-03-31 | $26.06M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $50.14M 10-K · filed 2020-02-26 |
| 2015-12-31 | $58.84M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |